Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation

Hiligsmann, Mickaël; Reginster, Jean‐Yves; Tosteson, Anna N.A.; Bukata, Susan V.; Saag, Kenneth G.; Gold, Deborah T.; Halbout, Philippe; Jiwa, Famida; Lewiecki, E. Michael; Pinto, Daniel; Adachi, Jonathan D.; Al-Daghri, Nasser M.; Bruyère, Olivier; Chandran, Manju; Cooper, Cyrus; Harvey, Nicholas C.; Einhorn, Thomas A.; Kanis, John А.; Kendler, David L.; Messina, Osvaldo Daniel; Rizzoli, René; Liu, Si; Silverman, Stuart L.

doi:10.1007/s00198-018-4744-x

Cited by 70 publications

(65 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reporting of this economic evaluation followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS), the recommendations of the Second Panel on Cost‐Effectiveness in Health and Medicine, and the recent recommendations for the conduct of economic evaluation in osteoporosis (Supplemental Table 1). We used an updated version of previously validated Markov microsimulation models to perform a cost‐effectiveness analysis among hypothetical cohorts of community‐dwelling osteoporotic women with previous vertebral fracture in the US at various ages of therapy initiation (65, 70, 75, and 80 years old). We chose to focus on white women for this analysis because they represent a high‐risk group for fracture .…”

Section: Methodsmentioning

confidence: 99%

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

2019

View full text Add to dashboard Cite

Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand the potential health economic impact of the availability of generic or biosimilar (generic/biosimilar) teriparatide. We examined the cost‐effectiveness of daily teriparatide for 2 years followed by weekly alendronate for 10 years (ie, sequential teriparatide/alendronate) compared with alendronate alone for 10 years in community‐dwelling white osteoporotic women with prior vertebral fracture at ages 65, 70, 75, and 80. Using an updated version of previously validated Markov microsimulation models, we obtained incremental cost‐effectiveness ratios (ICERs) (dollars [$] per quality‐adjusted life year [QALY]) with a willingness‐to‐pay (WTP) of $150,000 per QALY from a societal perspective with a lifelong time horizon. In the base case, we estimated the annual cost of teriparatide to be $20,161, based on the assumption of 10% brand usage (at a cost of $27,618) and 90% generic/biosimilar usage (priced 30% lower than brand). The ICERs of sequential teriparatide/alendronate compared with alendronate alone were greater than $280,000 per QALY at all ages examined. In deterministic sensitivity analyses, results were sensitive to teriparatide's cost, with the cost of a generic/biosimilar product needing to be 65% to 85% lower than brand for sequential teriparatide/alendronate to be cost‐effective. In probabilistic sensitivity analyses, under the assumption that the annual cost of teriparatide was $20,161, the probabilities of sequential teriparatide/alendronate being cost‐effective were less than 4% at a WTP of $150,000 per QALY. In conclusion, among community‐dwelling older osteoporotic women with prior vertebral fracture in the US, even with the potential availability of generic/biosimilar teriparatide, sequential teriparatide/alendronate would not be cost‐effective unless the cost of generic/biosimilar teriparatide were heavily discounted with respect to the current brand cost. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

2019

View full text Add to dashboard Cite

show abstract

“…Osteoporosis is an important health problem worldwide, the incidence of which is closely related to the increase of the elderly population and the decline of quality of life [1,2]. This systemic bone disease is mainly characterized by low bone mass and bone microstructural damage, which leads to increased bone fragility and fracture [1,2]. The primary goal of osteoporosis treatment is to prevent fractures, maintain or increase bone mineral density (BMD), and improve bone physiology [3,4].…”

Section: Introductionmentioning

confidence: 99%

Systematic Pharmacological Methodology to Explore the Pharmacological Mechanism of Siwu Decoction for Osteoporosis

et al. 2019

View full text Add to dashboard Cite

BackgroundOsteoporosis is an important health problem worldwide. Siwu decoction (SWD) and its modification have a good clinical effect on osteoporosis. However, the molecular mechanism of SWD on osteoporosis has not been thoroughly explained.Material/MethodsA systematic pharmacological methodology was utilized to predict the active compounds and potential targets of SWD, collect the genes of osteoporosis and the known targets of SWD, and analyze the osteoporosis and SWD’s network.ResultsFive networks were constructed and analyzed: (1) Osteoporosis genes’ protein–protein interaction (PPI) network; (2) Compound-compound target network of SWD; (3) SWD-osteoporosis PPI network; (4) Compound-known target network of SWD; and (5) SWD known target- osteoporosis PPI network. Several osteoporosis and treatment-related targets (eg.,. HSP90AB1, FGFR1, HRAS, GRB2, and PGF), clusters, biological processes, and signaling pathways (e.g., PI3K-Akt signaling pathway, insulin signaling pathway, MAPK signaling pathway and FoxO signaling pathway) were found.ConclusionsThe therapeutic effect of SWD on osteoporosis may be achieved by interfering with the biological processes and signaling pathways related to the development of osteoporosis.

show abstract

“…The results may lead to a set of special recommendations for conducting EEs of obstetric interventions. These recommendations should complement national and international guidelines, comparable to the set of recommendations developed in the field of osteoporosis 24 …”

Section: Discussionmentioning

confidence: 99%

Challenges in economic evaluations in obstetric care: a scoping review and expert opinion

Hulst

Brouwer

Mol

et al. 2020

BJOG

View full text Add to dashboard Cite

Objective The aim of this study is to identify items of economic evaluation guidelines that are frequently not complied within obstetric economic evaluations and to search for reasons for non‐adherence. Design Scoping review and qualitative study. Setting Literature on economic evaluations in obstetric care and interviews with experts. Population or sample The sample included 229 scientific articles and five experts. Methods A systematic literature search was performed. All types of literature about economic evaluations in obstetric care were included. The adherence to guidelines was assessed and articles were qualitatively analysed on additional information about reasons for non‐adherence. Issues that arose from the scoping review were discussed with experts. Main outcome measures Adherence to guideline items of the included economic evaluations studies. Analytical themes describing reasons for non‐adherence, resulting from qualitative analysis of articles and interviews with experts. Results A total of 184 economic evaluations and 45 other type of articles were included. Guideline items frequently not complied with were time horizon, type of economic evaluation and effect measure. Reasons for non‐adherence had to do with paucity of long‐term health data and assessing and combining outcomes for mother and child resulting from obstetric interventions. Conclusions This study identified items of guidelines that are frequently not complied with and the reasons behind this. The results are a starting point for a broad consensus building on how to deal with these challenges that can result in special guidance for the conduct of economic evaluations in obstetric care. Tweetable abstract Non‐adherence to guidelines in obstetric economic evaluation studies: the difficulties in detail.

show abstract

Cited by 70 publications

References 61 publications

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

Systematic Pharmacological Methodology to Explore the Pharmacological Mechanism of Siwu Decoction for Osteoporosis

Challenges in economic evaluations in obstetric care: a scoping review and expert opinion

Contact Info

Product

Resources

About